Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 2Breast 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Glioblastoma 1Cancer Related Cognitive Decline 1Brain Neoplasms 1

Interventions

pembrolizumab 213Cyclophosphamide 123Nivolumab 110Carboplatin 94fludarabine 81Gemcitabine 78Specimen Handling 74Bevacizumab 73Injections 71venetoclax 70Magnetic Resonance Spectroscopy 67Dexamethasone 66Paclitaxel 64Biopsy 59atezolizumab 57Cisplatin 54Ipilimumab 50Temozolomide 46Lenalidomide 43Azacitidine 43Docetaxel 42Pemetrexed 41Rituximab 40Radiotherapy 40Oxaliplatin 40Fluorouracil 39Cetuximab 38durvalumab 37Cytarabine 36Capecitabine 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × azeliragon × 1 year × Clear all
NCT05635734 2026-05-29

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Cantex Pharmaceuticals

Phase 1/2 Completed
33 enrolled
CNS

Glioblastoma

NCT05789589 2026-03-04

ADORATION

Baptist Health South Florida

Phase 1/2 Recruiting
46 enrolled
CNS

Brain Neoplasms, Neoplasm Metastasis, Neoplasms

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting
48 enrolled
Breast

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon âš¡